Literature DB >> 9708610

Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients.

Y Sakurauchi1, Y Matsumoto, T Shinzato, I Takai, Y Nakamura, M Sato, S Nakai, M Miwa, H Morita, T Miwa, I Amano, K Maeda.   

Abstract

Various muscle symptoms are well recognized among patients on maintenance hemodialysis. Carnitine deficiency may be an important factor of dialysis-associated muscle symptoms, whereas high-dose L-carnitine supplementation may result in unphysiologically high plasma levels of carnitine and carnitine esters. We studied the effect of low-dose L-carnitine treatment (500 mg/d) on muscle symptoms, plasma carnitine fractions, and lipid profiles in 30 periodically dialyzed patients with muscular weakness, fatigue, or cramps/aches. After 12 weeks of L-carnitine treatment, about two-thirds of patients had at least some improvement in muscular symptoms, whereas carnitine fractions were normal or slightly above normal ranges, but lipid profiles showed no demonstrable changes. This study also showed the correlation between plasma-free carnitine deficiency and months on dialysis. These results suggest that prolonged low-dose L-carnitine treatment can improve dialysis-associated muscle symptoms by restoring carnitine tissue levels and washing out acyl moieties.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708610     DOI: 10.1053/ajkd.1998.v32.pm9708610

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial.

Authors:  Lucile Mercadal; Mathieu Coudert; Anne Vassault; Laurence Pieroni; Alain Debure; Messaoud Ouziala; Hélène Depreneuf; Christine Fumeron; Aude Servais; Nader Bassilios; Jacques Bécart; Ubald Assogba; Mahmoud Allouache; Boussad Bouali; Nhan Luong; Marie Paul Dousseaux; Sophie Tezenas-du Montcel; Gilbert Deray
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 8.237

2.  L-carnitine supplementation and EPO requirement in children on chronic hemodialysis.

Authors:  Bilal Aoun; Etienne Bérard; Renata Vitkevic; Axelle Dehée; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2009-08-07       Impact factor: 3.714

3.  Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint.

Authors:  Vittorio Sirolli; Claudia Rossi; Augusto Di Castelnuovo; Paolo Felaco; Luigi Amoroso; Mirco Zucchelli; Domenico Ciavardelli; Carmine Di Ilio; Paolo Sacchetta; Sergio Bernardini; Arduino Arduini; Mario Bonomini; Andrea Urbani
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

4.  Fatigue in chronic peritoneal dialysis patients.

Authors:  Shahrzad Ossareh; Jamshid Roozbeh; Murali Krishnan; Vassilios Liakopoulos; Joanne M Bargman; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

Review 5.  Pharmacokinetics of L-carnitine.

Authors:  Allan M Evans; Gianfranco Fornasini
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Comparison of vitamin e and L-carnitine, separately or in combination in patients with intradialytic complications.

Authors:  Hamid Tayebi Khosroshahi; Bohlul Habibi Asl; Afshin Habibzadeh; Parastoo Chaichi; Amin Ghanbarpour; Amir Hossein Badie
Journal:  Nephrourol Mon       Date:  2013-07-07

Review 7.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

8.  Screening of Free Carnitine and Acylcarnitine Status in Children With Familial Mediterranean Fever.

Authors:  Ertuğrul Kiykim; Ayşe Çiğdem Aktuğlu Zeybek; Kenan Barut; Tanyel Zübarioğlu; Mehmet Şerif Cansever; Şeyda Alsancak; Özgür Kasapçopur
Journal:  Arch Rheumatol       Date:  2016-03-10       Impact factor: 1.472

Review 9.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

10.  Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS).

Authors:  Shota Matsufuji; Tetsuo Shoji; Suhye Lee; Masao Yamaguchi; Mari Nishimura; Yoshihiro Tsujimoto; Shinya Nakatani; Tomoaki Morioka; Katsuhito Mori; Masanori Emoto
Journal:  Nutrients       Date:  2022-01-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.